Day 2 :
The University of Texas MD Anderson Cancer Center, USA
Keynote: MicroRNA expression profiling to identify potential biomarkers in inflammatory breast cancer
Time : 09:00-09:30
Dr. Lei Huo received her Bachelor of Medicine degree at Beijing Medical University and her PhD in Molecular Biology and Genetics at Northwestern University, Chicago. A practicing breast pathologist in MD Anderson Cancer Center, she is actively involved in clinical and translational research in the field of breast cancer. Her research interests include molecular and immunohistochemical markers in the diagnosis and treatment of breast cancer, among others.
Inflammatory breast cancer is characterized by clinical hallmarks of diffuse erythema and edema (peau d’orange) involving one third or more of the breast skin caused by tumor emboli blocking dermal lymphatics, and rapid progression from the onset of the disease. It is the most aggressive form of breast cancer, comprising 1-5% of newly diagnosed breast cancer in the United States. The survival outcomes of patients with inflammatory breast cancer are poor with standard therapy. There is an urgent need for new therapeutic targets. At the molecular level, the few published mRNA expression profiling studies have indicated that transcriptional heterogeneity exists in inflammatory breast cancer as extensively as in non-inflammatory breast cancer. Recent advances have implicated the role of microRNA as oncogenes or tumor suppressor genes in tumorigenesis, metastasis and response to treatment in various cancer types including breast cancer. In our recent study, the microRNA expression profiles of 23 inflammatory breast cancer, 24 non-inflammatory advanced breast cancer and 12 normal breast tissue fresh frozen samples were generated using a previously validated microRNA microarray assay. Among the differentially expressed microRNAs, microRNA-205 expression was decreased not only in tumor compared with normal breast tissue, but also in inflammatory breast cancer compared with non-inflammatory breast cancer. Lower expression of microRNA-205 correlated with worse distant metastasis-free survival and overall survival in our cohort. Thus, microRNA-205 may serve as a therapeutic target in advanced breast cancer including inflammatory breast cancer.
Vardhman Mahavir Medical College, India
Time : 09:55-10:20
Dr. Chintamani specialises in oncosurgery. He is the President of Association of Breast Surgeons of India and the Governing council member of Association of Surgeons of India.He is a tutor and examiner at Royal College of Surgeons of Edinburgh, UK.
Management of breast cancer ,arguably the commonest cancer of mankind has indeed undergone a tremendous evolution in the last few decades. While there are variations in the presentation and behaviour of this cancer, there are few accepted common management strategies that have been adopted world over. Till such time that we have completely reliable and rock solid guidelines there would be regional variations in the management and outcome of this dreaded but curable cancer. The management approaches would also vary depending on the availability of healthcare resources and proper investigational and management facilities. The management would therefore need to be tailored to the centre, the patient and also the expertise available.
While there are no issues with these modalities being available in the developed world, there are problems in the developing world, although one can find some of these countries as healthcare paradoxes i.e at one end there are centres of excellence and at the other end there are issues relating to providing primary health care and management of certain basic health problems like communicable diseases. There is thus no uniformity in the management of breast cancer across centres and countries. Quality assurance has to be ensured in order to achieve acceptable and reproducible outcomes in the management of breast cancer across the globe.